Viking Therapeutics (VKTX) Liabilities and Shareholders Equity (2014 - 2026)

Viking Therapeutics has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $608.2 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $608.2 million, down 29.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 billion (down 21.01% YoY), and the FY2025 annual result was $715.7 million, down 21.2% from the prior year.
• Liabilities and Shareholders Equity came in at $608.2 million for Q1 2026 at Viking Therapeutics, down from $715.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $967.5 million in Q1 2024 to a low of $150.9 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $608.2 million (2026), against an average of $560.8 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 541.19% in 2024 and dropped 29.84% in 2026, its largest moves.
• Viking Therapeutics' Liabilities and Shareholders Equity stood at $168.5 million in 2022, then jumped by 118.65% to $368.5 million in 2023, then soared by 146.5% to $908.3 million in 2024, then dropped by 21.2% to $715.7 million in 2025, then retreated by 15.02% to $608.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $608.2 million (Q1 2026), $715.7 million (Q4 2025), and $739.4 million (Q3 2025), per Business Quant data.